RxDoctor Payments Data

Katherine Hedian, DO

Family Medicine · Esmont, VANPI 1437563392

Payments from drug & device makers

$907in general payments, 2019–2025

Across 52 payments — averaging $17.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$315
  • Lilly USA, LLC$152
  • Pfizer$126
  • GSK$77
  • Novo Nordisk$57
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$53
  • plus $126 from 4 others

What the payments were for

  • Food & beverage$907100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$907 in reported general payments places this provider in the 65th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$11,809
Medicare patients
89
Services billed
327

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin84$84,582
OzempicSemaglutide48$53,540
TrulicityDulaglutide36$47,106
MounjaroTirzepatide44$45,300
RybelsusSemaglutide37$44,586
EliquisApixaban26$37,121
LinzessLinaclotide20$25,286
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$23,026
VraylarCariprazine Hcl12$19,677
XareltoRivaroxaban17$17,760
Lantus SolostarInsulin Glargine,hum.Rec.Anlog39$9,447
Stiolto RespimatTiotropium Br/Olodaterol Hcl13$8,079
Ondansetron Hcl35$8,045
LantusInsulin Glargine,hum.Rec.Anlog22$4,611
ShingrixVaricella-Zoster Ge/As01b/Pf21$4,383

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$57$98,12685 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog$152$95,43991 claims
AbbVieLinzess, Vraylar$315$44,96432 claims
PfizerEliquis$126$37,12126 claims
GSKTrelegy Ellipta, Shingrix$77$27,40945 claims
AstraZenecaSymbicort$41$4,28712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Esmont

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →